Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 353 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | December 04, 2016

7 of the Most Shocking Biotech Pipeline Blowups of 2016

Drug development is a tough business. Here's a closer look at seven of the biggest biotech flops of the year.

Investing | November 30, 2016

Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today

Shares collapsed after the company announced that it will discontinue development of some of its most promising product candidates.

Investing | November 22, 2016

5 Biotech Stocks George Soros Is Buying

The Soros Fund showed a healthy appetite for biotech stocks in Q3 -- ignoring the political risk.

Investing | November 20, 2016

Ready to Get In on Biotech? Check Out These 3 Stocks

Our team of healthcare experts thinks that these three biotech stocks are great choices for beginners.

Investing | November 10, 2016

What's Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?

Arrowhead's stock cratered after the announcement of an FDA clinical hold. Can the biotech make a comeback?

Investing | November 06, 2016

Is AbbVie's Dividend Worth the Risk?

An attractively high dividend rate may have AbbVie on income investors' radar, but there are a few things investors should know about this company before they dive in and buy the stock for its dividend payout.

Investing | November 04, 2016

Why AbbVie Shares Tumbled 11.6% in October

In anticipation of what proved to be disappointing third-quarter financial results, investors reduced their positions in the big-cap biotech stock.

Investing | November 02, 2016

Gilead's Q3 Bombshell: No More Hepatitis C R&D

Gilead Sciences is shifting its R&D budget away from the development of additional hepatitis C drugs.

Investing | October 28, 2016

5 Things Amgen Inc.'s Management Wants You to Know

Here's what you need to know about what Amgen's management said in the biotech's Q3 earnings call.

Investing | October 09, 2016

3 Cancer Drugs That Could Get an FDA OK Next Year

Cancer drug development is costly and fraught with failure, but these three companies have successfully navigated clinical trials and as a result, each has a chance at winning FDA approval of their drugs in 2017.

Results 1 - 10 of 353 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology